Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism

CMAJ. Canadian Medical Association Journal

Volumn 163, Issue 8, 2000, Pages 1016-1021

  Bates, S M ^a   Ginsberg, J S ^a   Straus, S E ^a   Rekers, H ^a   Sackett, D L ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ORAL CONTRACEPTIVE AGENT;

ANTICOAGULANT THERAPY; DISEASE ASSOCIATION; HEMOSTASIS; HUMAN; LABORATORY TEST; PROPHYLAXIS; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034680297     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. The familial tendency in thromboembolic disease
2. Inherited antithrombin deficiency causing thrombophilia
3. Thrombosis in antithrombin III deficient persons: Report of a large kindred and literature review
4. Complete nucleotide sequence of the antithrombin gene: Evidence for homologous recombination causing thrombophilia
5. Molecular genetics of antithrombin deficiency
6. Antithrombin III mutation database: First update
7. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
8. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
9. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
10. The long-term clinical course of acute venous thrombosis
11. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
12. Laboratory screening of inherited thrombotic syndromes
13. Approach to the thrombophilic patient
14. Familial thrombophilia: A review analysis
15. Inappropriate use of laboratory services: Long-term combined approach to modify request patterns
16. Inappropriate use of cerebrospinal fluid Venereal Disease Research Laboratory (VDRL) test to exclude neurosyphilis
17. Inappropriate testing for diarrheal diseases in the hospital
18. Inappropriate urine cultures in hospitalized patients receiving antibiotic therapy
19. Serum complements: Inappropriate use in patients with suspected rheumatic disease
20. The environment and disease: Association or causation?
21. Users' guide to the medical literature. IV. How to use an article about harm
22. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests
23. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients
24. Heparin-induced decrease in circulating antithrombin III
25. Antithrombin-III transfusion in disseminated intravascular coagulation
26. Deficiencies of protein C, an inhibitor of blood coagulation
27. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states
28. Behavior of protein S during long-term oral anticoagulant therapy
29. Antithrombin III in oral contraceptive users and during normotensive pregnancy
30. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study
31. Immune coagulation disorders
32. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
33. Identification of the same factor V mutation in 47 out of 60 thrombosis-prone families with inherited resistance to activated protein C
34. Hyperhomocysteinemia as a risk factor for deep vein thrombosis
35. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
36. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case control study (Transnational Research Group on Oral Contraceptives and the Health of Young Women)
37. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components
38. Effect of different prostagens in low oestrogen oral contraceptives on venous thromboembolic disease: World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception
39. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
40. The differential risk of oral contraceptives: The impact of full exposure history
41. First-time use of newer oral contraceptives and the risk of venous thromboembolism
42. Normalized activated protein C Ratio itself not associated with increased risk of venous thromboembolism
43. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: A blinded clinical evaluation [abstract 640]. XVIIth Congress of the International Society on Thrombosis and Haemostasis; 1999 Aug 14-21; Washington
44. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study